[{"from": "human", "value": "Provide a brief overview of this molecule. [C][C][Branch2][Branch1][=C][C][=Branch1][C][=O][N][Branch2][Ring1][N][C][=Branch1][C][=S][N][Ring1][#Branch1][C][=C][N][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][C][C][C][C][=N][C][=C][O][Ring1][Branch1][C][=C][Branch2][Ring1][Branch1][C][=Branch1][#Branch2][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][C][#N][C][Branch1][C][F][Branch1][C][F][F][F][C]"}, {"from": "gpt", "value": "The molecule is an orally bioavailable androgen receptor (AR) antagonist with potential antineoplastic activity. Upon oral administration, proxalutamide binds to AR in target tissues, inhibits androgen-induced receptor activation, and facilitates the formation of inactive complexes that cannot translocate to the nucleus. This prevents binding to and transcription of AR-responsive genes that regulate prostate cancer cell proliferation. In addition, proxalutamide induces AR downregulation, thereby further preventing AR-mediated signaling. This ultimately leads to an inhibition of growth in AR-expressing prostate cancer cells. AR is overexpressed in prostate cancer and plays a key role in prostate cancer cell proliferation."}]